Amgen scores Otezla patent win, protecting its blockbuster from Sandoz and Zydus generics until 2028

When Amgen bought marketing rights to psoriasis pill Otezla for $13.4 billion two years ago, the company was likely counting on not having to compete against early generics. And now, thanks to a win in court, Amgen appears poised to enjoy several more years of exclusivity in the key U.S. market.